TD Cowen analyst Ritu Baral has maintained their bullish stance on GHRS stock, giving a Buy rating yesterday.
Ritu Baral has given her Buy rating due to a combination of factors that highlight GH Research’s promising developments and financial stability. The company has shown impressive results in its Phase 2b trial for GH001, an inhaled treatment for treatment-resistant depression (TRD). The trial demonstrated significant reductions in depression scores and a high remission rate, with the treatment being well-tolerated and no serious adverse events reported. This positive data supports the potential of GH001 as a viable treatment option, which could drive future growth for the company.
Additionally, GH Research’s financial position is strong, with a substantial cash balance that is expected to sustain operations into 2026. The anticipated completion of the open-label extension study and the expected lifting of the FDA clinical hold on their proprietary aerosol device further bolster the company’s prospects. These factors combined suggest a favorable outlook for GH Research, justifying the Buy rating.
In another report released yesterday, JMP Securities also reiterated a Buy rating on the stock with a $39.00 price target.